Avadel Pharmaceuticals plc (NASDAQ:AVDL) Receives $24.57 Average PT from Brokerages

Avadel Pharmaceuticals plc (NASDAQ:AVDL) has earned a consensus recommendation of “Buy” from the seven analysts that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have covered the stock in the last year is $24.57.

A number of research firms have issued reports on AVDL. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Avadel Pharmaceuticals in a research note on Wednesday, September 4th. Rodman & Renshaw began coverage on Avadel Pharmaceuticals in a research note on Wednesday, June 12th. They issued a “buy” rating and a $27.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Avadel Pharmaceuticals in a research note on Wednesday, August 28th.

Institutional Trading of Avadel Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVDL. Janus Henderson Group PLC boosted its stake in Avadel Pharmaceuticals by 16.1% in the 1st quarter. Janus Henderson Group PLC now owns 12,915,160 shares of the company’s stock worth $218,182,000 after purchasing an additional 1,789,830 shares during the period. Gendell Jeffrey L raised its holdings in Avadel Pharmaceuticals by 1.7% during the 1st quarter. Gendell Jeffrey L now owns 5,708,118 shares of the company’s stock valued at $96,410,000 after buying an additional 92,768 shares during the period. Brandes Investment Partners LP increased its stake in Avadel Pharmaceuticals by 1.5% in the second quarter. Brandes Investment Partners LP now owns 1,483,439 shares of the company’s stock worth $20,894,000 after purchasing an additional 21,214 shares during the period. Kennedy Capital Management LLC increased its stake in Avadel Pharmaceuticals by 1.1% in the first quarter. Kennedy Capital Management LLC now owns 653,147 shares of the company’s stock worth $11,032,000 after purchasing an additional 7,273 shares during the period. Finally, Modera Wealth Management LLC increased its stake in Avadel Pharmaceuticals by 0.4% in the second quarter. Modera Wealth Management LLC now owns 602,608 shares of the company’s stock worth $8,473,000 after purchasing an additional 2,159 shares during the period. Hedge funds and other institutional investors own 69.19% of the company’s stock.

Avadel Pharmaceuticals Trading Down 1.5 %

AVDL stock opened at $13.40 on Wednesday. Avadel Pharmaceuticals has a twelve month low of $9.50 and a twelve month high of $19.09. The company has a market capitalization of $1.29 billion, a P/E ratio of -7.20 and a beta of 1.53. The firm has a 50 day simple moving average of $15.51 and a 200-day simple moving average of $15.94.

Avadel Pharmaceuticals (NASDAQ:AVDL) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. Avadel Pharmaceuticals had a negative net margin of 111.64% and a negative return on equity of 122.64%. The business had revenue of $41.50 million during the quarter, compared to the consensus estimate of $37.47 million. During the same quarter last year, the company earned ($0.70) earnings per share. The business’s quarterly revenue was up 2666.7% compared to the same quarter last year. On average, research analysts predict that Avadel Pharmaceuticals will post -0.5 EPS for the current year.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.